Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 9, No 1 (2016) MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 Abstract  similar documents
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
"... inclusion and exclusion into the reimbursement lists in Russian Federation. The liner mathematical model ..."
 
Vol 11, No 3 (2018) The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia Abstract  similar documents
V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina
"... the principles of health technologies assessment (HTA) and the reimbursement strategies in Russia have been put ..."
 
Vol 11, No 3 (2018) What is the role of antineoplastic drug safety in reimbursement decision making? Abstract  similar documents
A. S. Kolbin, A. A. Kurylev
"... in the decision making on reimbursement and inclusion/noninclusion into VeD lists. Yet the total safety score ..."
 
Vol 12, No 2 (2019) Health technology assessment and reimbursement of pharmaceuticals in Italy Abstract  similar documents
F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan
"... ) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-listing ..."
 
Vol 12, No 4 (2019) The health technology assessment system in Australia Abstract  similar documents
V. V. Omelyanovskiy, E. S. Saybel, T. P. Bezdenezhnykh, G. R. Khachatryan
"... implications of including the drug in the reimbursement list, and consideration of any other factors that may ..."
 
Vol 8, No 1 (2015) PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION Abstract  similar documents
L. S. Melnikova
"... are used in foreign countries at reimbursement of costs for public drug supply. The author estimates ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
 
Vol 13, No 2 (2020) Affordability of in vivo gene therapy. Problems and potential solutions Abstract  similar documents
V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko
"... not reveal general methodological peculiarities. The analysis of the approaches to the reimbursement ..."
 
Vol 7, No 4 (2014) IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? Abstract  similar documents
V. V. Omelyanovskiy
"... reimbursement) shows a substantial variety and presence of national peculiarities; however the majority ..."
 
Vol 7, No 4 (2014) ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva
"... for 25 drugs for treatment of malignant neoplasms and cardiovascular diseases, included in the list ..."
 
Vol 10, No 1 (2017) RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION Abstract  similar documents
M. V. Sura
"... and sources of finance pertaining to the restrictive lists of drugs, which play a substantial role in the drug ..."
 
Vol 11, No 4 (2018) Patient registers and account registries of compulsory medical insurance: integration and replaceability Abstract  similar documents
I. A. Zheleznyakova, G. I. Pirova, E. A. Proxorovich
 
Vol 13, No 2 (2020) Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871 Abstract  similar documents
V. V. Omelyanovskiy, E. A. Maksimkina, O. I. Ivakhnenko, M. V. Avxentyeva, M. V. Sura, G. R. Khachatryan
"... investigation. The changes affecting both the order and the procedure of forming the lists of medical drugs ..."
 
Vol 10, No 1 (2017) PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS Abstract  similar documents
A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina
"... that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
 
1 - 16 of 16 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)